For the readers interested in the stock health of Autolus Therapeutics plc (AUTL). It is currently valued at $7.62. When the transactions were called off in the previous session, Stock hit the highs of $7.69, after setting-off with the price of $7.28. Company’s stock value dipped to $7.25 during the trading on the day. When the trading was stopped its value was $7.39.
Recently in News on June 15, 2021, Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL. Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received innovative licensing and access pathway (ILAP) designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for AUTO1 (obecabtagene autoleucel, obe-cel), the company’s CAR T cell therapy being investigated in the ongoing FELIX Phase 1b/2 study in relapsed / refractory (r/r) adult B-cell Acute Lymphocytic Leukemia (ALL) in patients 18 years and older. You can read further details here
Autolus Therapeutics plc had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $9.98 on 01/07/21, with the lowest value was $4.60 for the same time period, recorded on 05/11/21.
Autolus Therapeutics plc (AUTL) full year performance was -42.14%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Autolus Therapeutics plc shares are logging -55.67% during the 52-week period from high price, and 65.65% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $4.60 and $17.19.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 3436196 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Autolus Therapeutics plc (AUTL) recorded performance in the market was -14.77%, having the revenues showcasing 11.08% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 476.10M, as it employees total of 376 workers.
Autolus Therapeutics plc (AUTL) in the eye of market guru’s
During the last month, 7 analysts gave the Autolus Therapeutics plc a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 4 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 6.46, with a change in the price was noted -1.28. In a similar fashion, Autolus Therapeutics plc posted a movement of -14.38% for the period of last 100 days, recording 1,312,106 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for AUTL is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Autolus Therapeutics plc (AUTL): Stocks Technical analysis and Trends
Raw Stochastic average of Autolus Therapeutics plc in the period of last 50 days is set at 83.20%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 72.52%. In the last 20 days, the company’s Stochastic %K was 69.41% and its Stochastic %D was recorded 75.10%.
If we look into the earlier routines of Autolus Therapeutics plc, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -14.77%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -6.27%, alongside a downfall of -42.14% for the period of the last 12 months. The shares increased approximately by 11.24% in the 7-day charts and went down by 17.59% in the period of the last 30 days. Common stock shares were driven by 11.08% during last recorded quarter.